# Progress in the application of sustained-release drug microspheres in tissue engineering **Authors:** Lian Ruan, Mengrong Su, Xinyun Qin, Qingting Ruan, Wen Lang, Minhui Wu, Yujie Chen, Qizhuang Lv PMC · DOI: 10.1016/j.mtbio.2022.100394 · Materials Today Bio · 2022-08-13 ## TL;DR This paper reviews how sustained-release drug microspheres are used in tissue engineering, covering their types, preparation, and future potential. ## Contribution A systematic review of sustained-release drug microspheres in tissue engineering, highlighting their applications and future directions. ## Key findings - Sustained-release drug microspheres offer targeted and long-term drug delivery in tissue engineering. - Various preparation methods and materials are used to create these microspheres. - The paper identifies current limitations and suggests future research directions for improvement. ## Abstract Sustained-release drug-loaded microspheres provide a long-acting sustained release, with targeted and other effects. There are many types of sustained-release drug microspheres and various preparation methods, and they are easy to operate. For these reasons, they have attracted widespread interest and are widely used in tissue engineering and other fields. In this paper, we provide a systematic review of the application of sustained-release drug microspheres in tissue engineering. First, we introduce this new type of drug delivery system (sustained-release drug carriers), describe the types of sustained-release drug microspheres, and summarize the characteristics of different microspheres. Second, we summarize the preparation methods of sustained-release drug microspheres and summarize the materials required for preparing microspheres. Third, various applications of sustained-release drug microspheres in tissue engineering are summarized. Finally, we summarize the shortcomings and discuss future prospects in the development of sustained-release drug microspheres. The purpose of this paper was to provide a further systematic understanding of the application of sustained-release drug microspheres in tissue engineering for the personnel engaged in related fields and to provide inspiration and new ideas for studies in related fields. Image 1 ## Full-text entities - **Genes:** Ngf (nerve growth factor) [NCBI Gene 310738] {aka Ngfb, beta-NGF}, Alb (albumin) [NCBI Gene 11657] {aka Alb-1, Alb1, BCL001, BCL002, BPL001}, Fgf2 (fibroblast growth factor 2) [NCBI Gene 14173] {aka Fgf-2, Fgf2a, Fgfb, bFGF}, SHH (sonic hedgehog signaling molecule) [NCBI Gene 6469] {aka HHG1, HLP3, HPE3, MCOPCB5, SMMCI, ShhNC}, Shh (sonic hedgehog signaling molecule) [NCBI Gene 29499] {aka ShhNC}, BMP2 (bone morphogenetic protein 2) [NCBI Gene 650] {aka BDA2, BMP2A, SSFSC, SSFSC1}, SGPL1 (sphingosine-1-phosphate lyase 1) [NCBI Gene 8879] {aka NPHS14, RENI, S1PL, SPL}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, Tjp1 (tight junction protein 1) [NCBI Gene 21872] {aka ZO1}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p} - **Diseases:** atrophy (MESH:D001284), Bone defects (MESH:D001847), Nerve injury (MESH:D000080902), deformity (MESH:D009140), joint pain (MESH:D018771), nervous system injury (MESH:D020196), cytotoxic (MESH:D064420), death (MESH:D003643), Skin wounds (MESH:D014947), blood coagulation (MESH:D001778), osteoarthritis (MESH:D010003), chronic trauma (MESH:D002908), infertility (MESH:D007246), abdominal pain (MESH:D015746), cryptococcosis (MESH:D003453), fever (MESH:D005334), infection (MESH:D007239), gout arthritis (MESH:D006073), Arthritis (MESH:D001168), diarrhea (MESH:D003967), fungal (MESH:D009181), degenerative lesions (MESH:D019636), rheumatoid arthritis (MESH:D001172), burn (MESH:D002056), swelling (MESH:D004487), cancer (MESH:D009369), diabetic (MESH:D003920), Reproductive disease (MESH:D060737), bacterial infection of the (MESH:D001424), peripheral nerve injuries (MESH:D059348), ectopic osteogenesis (MESH:C566852), colon mucosal damage (MESH:D003108), skin injuries (MESH:D000069836), colitis (MESH:D003092), ovarian cancer (MESH:D010051), tract (MESH:D014570), inflammation (MESH:D007249), schizophrenia (MESH:D012559), ovarian cysts (MESH:D010048), carcinogenesis (MESH:D063646), articular cartilage injury (MESH:D002357), CS (MESH:C535787), pain (MESH:D010146), infectious arthritis (MESH:D001170), hypoglycemia (MESH:D007003), acute enteritis (MESH:D004751), spinal cord injuries (MESH:D013119), autoimmune factors (MESH:D001327), Wallerian degeneration (MESH:D014855) - **Species:** Atractylodes macrocephala (species) [taxon 265785], Mus musculus (house mouse, species) [taxon 10090], Codonopsis pilosula (species) [taxon 86864], Hysterothylacium sp. SA (species) [taxon 1884613], Panax notoginseng (notoginseng, species) [taxon 44586], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Escherichia coli (E. coli, species) [taxon 562], Bos taurus (bovine, species) [taxon 9913] - **Mutations:** C-32 C - **Cell lines:** SVF — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_UI86), PC12 — Rattus norvegicus (Rat), Rat adrenal gland pheochromocytoma, Cancer cell line (CVCL_0481) ## Full text _Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC9420381/full.md ## Figures 9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC9420381/full.md ## References 212 references — full list in the complete paper: https://tomesphere.com/paper/PMC9420381/full.md --- Source: https://tomesphere.com/paper/PMC9420381